Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces-2009-2010

被引:32
|
作者
Mayet, Aurelie [1 ]
Ligier, Caroline [1 ]
Gache, Kristel [1 ]
Manet, Ghislain [1 ]
Nivoix, Philippe [2 ]
Dia, Aissata [2 ]
Haus-Cheymol, Rachel [1 ]
Verret, Catherine [1 ]
Duron, Sandrine [1 ]
Faure, Nina [2 ]
Piarroux, Martine [2 ]
De Laval, Frank [2 ]
Simon, Fabrice [3 ]
Decam, Christophe [2 ]
Chaudet, Herve [2 ]
Meynard, Jean-Baptiste [1 ]
Rapp, Christophe [4 ]
Deparis, Xavier [2 ]
Migliani, Rene [1 ]
机构
[1] Ecole Val de Grace, Dept Epidemiol & Sante Publ Nord, Paris, France
[2] Inst Med Trop Serv Sante Armees, Dept Epidemiol & Sante Publ Sud, Marseille, France
[3] Hop Instruct Armees Laveran, Serv Pathol Infect & Trop, Marseille, France
[4] Hop Instruct Armees Begin, Serv Pathol Infect & Trop, St Mande, France
关键词
Influenza; Military forces; Pandemic; Vaccine; Vaccine adverse event; GUILLAIN-BARRE-SYNDROME; A VIRUS;
D O I
10.1016/j.vaccine.2011.01.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the face of the A(H1N1) 2009 influenza pandemic, in October 2009 the French military health service (SSA) initiated a large vaccination campaign with Pandemrix (R) vaccine in the military forces. The aim of this study was to describe vaccine adverse events (VAE) reported during this campaign. Methods: VAE and the number of people vaccinated were surveyed by the SSA Epidemiological network across all military forces during the campaign, from October 2009 to April 2010. For each case, a notification form was completed, providing patient and clinical information. Three types of VAE were considered: non-serious, serious and unexpected. Results: There were 315.4 reported VAE per 100,000 vaccinations. Vaccination and VAE incidence rate peaks coincided with influenza epidemic peak in early December. The number of injected doses was 49,138, corresponding to a 14.5% vaccination coverage among military personnel, and 155 VAE were reported, including 5 serious VAE (1 Guillain-Barre syndrome, 2 malaises and 1 convulsive episode). Most VAE were non-serious (97.1%). Among these, 6 cases of local, rapidly regressive paresthesia were observed. Discussion: The military VAE surveillance system constitutes the only observatory on benign VAE in France. The reporting rate was much higher after the pandemic vaccine than after the seasonal vaccine, which may be a reflection of stimulated reporting. This report provides a useful description of VAE among military personnel during a mass emergency vaccination program, showing that the tolerance of the pandemic vaccine appeared acceptable. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2576 / 2581
页数:6
相关论文
共 50 条
  • [31] The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children
    Blyth, Christopher C.
    Richmond, Peter C.
    Jacoby, Peter
    Thornton, Patrick
    Regan, Annette
    Robins, Christine
    Kelly, Heath
    Smith, David W.
    Effler, Paul V.
    VACCINE, 2014, 32 (32) : 4075 - 4081
  • [32] Risk of Adverse Fetal Outcomes Following Administration of a Pandemic Influenza A(H1N1) Vaccine During Pregnancy
    Pasternak, Bjorn
    Svanstrom, Henrik
    Molgaard-Nielsen, Ditte
    Krause, Tyra G.
    Emborg, Hanne-Dorthe
    Melbye, Mads
    Hviid, Anders
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (02): : 165 - 174
  • [33] Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010
    Ouandaogo, Claude-Roger
    Yameogo, Tene M.
    Diomande, Fabien V. K.
    Sawadogo, Charles
    Ouedraogo, Bassirou
    Ouedraogo-Traore, Rasmata
    Pezzoli, Lorenzo
    Djingarey, Mamoudou H.
    Mbakuliyemo, Nehemie
    Zuber, Patrick L. F.
    VACCINE, 2012, 30 : B46 - B51
  • [34] Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom
    Pebody, R. G.
    Andrews, N.
    Fleming, D. M.
    McMenamin, J.
    Cottrell, S.
    Smyth, B.
    Durnall, H.
    Robertson, C.
    Carman, W.
    Ellis, J.
    Sebastian-Pillai, P.
    Zambon, M.
    Kearns, C.
    Moore, C.
    Thomas, D. Rh.
    Watson, J. M.
    EPIDEMIOLOGY AND INFECTION, 2013, 141 (03) : 620 - 630
  • [35] Case-based reported mortality associated with laboratory-confirmed influenza A(H1N1) 2009 virus infection in the Netherlands: the 2009-2010 pandemic season versus the 2010-2011 influenza season
    van Gageldonk-Lafeber, Rianne A. B.
    Riesmeijer, Rob M.
    Friesema, Ingrid H. M.
    Meijer, Adam
    Isken, Leslie D.
    Timen, Aura
    van der Sande, Marianne A. B.
    BMC PUBLIC HEALTH, 2011, 11
  • [36] Adverse Events following Immunization (AEFI) with the Novel Influenza A (H1N1) 2009 Vaccine: Findings from the National Registry of All Vaccine Recipients and AEFI and the Passive Surveillance System in South Korea
    Kim, Jong-Hee
    Cho, Hee-Yeon
    Hennessey, Karen A.
    Lee, Hoan Jong
    Bae, Geun Ryang
    Kim, Hyeon Chang
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2012, 65 (02) : 99 - 104
  • [37] Case-based reported mortality associated with laboratory-confirmed influenza A(H1N1) 2009 virus infection in the Netherlands: the 2009-2010 pandemic season versus the 2010-2011 influenza season
    Rianne AB van Gageldonk-Lafeber
    Rob M Riesmeijer
    Ingrid HM Friesema
    Adam Meijer
    Leslie D Isken
    Aura Timen
    Marianne AB van der Sande
    BMC Public Health, 11
  • [38] Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010
    Parrella, Adriana
    Gold, Michael
    Marshall, Helen
    Braunack-Mayer, Annette
    Watson, Maureen
    Baghurst, Peter
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (05) : 662 - 667
  • [39] Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015
    Moro, Pedro L.
    Winiecki, Scott
    Lewis, Paige
    Shimabukuro, Tom T.
    Cano, Maria
    VACCINE, 2015, 33 (48) : 6684 - 6688
  • [40] Pandemic Influenza (A/H1N1) Vaccine Uptake among French Private General Practitioners: A Cross Sectional Study in 2010
    Verger, Pierre
    Flicoteaux, Remi
    Schwarzinger, Michael
    Sagaon-Teyssier, Luis
    Peretti-Watel, Patrick
    Launay, Odile
    Sebbah, Remy
    Moatti, Jean-Paul
    PLOS ONE, 2012, 7 (08):